Menu

COVID-19 Frontline Therapies: Navigating Through This Health Crisis and Optimizing Patient Care

When:
July 22, 2021 @ 6:00 pm – 7:00 pm
2021-07-22T18:00:00+00:00
2021-07-22T19:00:00+00:00

COVID-19 Frontline Therapies: Navigating Through This Health Crisis and Optimizing Patient Care

REGISTER FOR LIVE VIRTUAL PROGRAM

Thursday, July 22, 2021

6:00 PM – 7:00 PM CT

This virtual program is at 7:00 PM Eastern, 6:00 PM Central, 5:00 PM Mountain, and 4:00 PM Pacific

Program Features

    • Whiteboard Animations
    • Interactive, case-based learning environment
    • Complimentary Personalized Online Poster Portal

Faculty

Juri Boguniewicz, MD
Assistant Professor of Pediatrics
Section of Infectious Diseases
University of Colorado School of Medicine
Aurora, CO

Program Description

This program provides a comprehensive and up-to-date perspective on the ever-changing management of patients with COVID-19 who present to the emergency department. The session features in-depth case studies to encourage retention of the lessons and provide new perspectives on the management of patients during the COVID-19 pandemic. The case studies will focus on different issues facing clinicians, such as identifying patients who would benefit from monoclonal antibody therapy and best practices for incorporating agents authorized for emergency use into the care of hospitalized and non-hospitalized patients with COVID-19. Strategies for administering neutralizing monoclonal antibodies, such as referral to local infusion centers or developing in-clinic infusion capabilities, will also be discussed.

Target Audience

This CME initiative is designed for HCPs who are involved in the care and treatment of patients with COVID-19, including physicians, NPs, PAs, nurses, and pharmacists across emergency medicine, primary care, family medicine, infusion centers, and the Department of Veteran Affairs.

Learning Objectives

After completing the CME activity, learners should be better able to:

  • Assess the rationale for the use of new virus-neutralizing monoclonal antibodies to mitigate the risk of viral resistance to therapy
  • Critique the efficacy and safety of new virus-neutralizing monoclonal antibody therapies and other therapies approved for emergency use in all patients who test positive for COVID-19
  • Develop in-clinic infusion capability in order to administer new virus-neutralizing monoclonal antibodies to patients with COVID-19 at the point-of-care
  • Use guidance and resources developed to promote safe and responsible use of infusion therapies for treating patients with COVID-19

Accreditation Statement

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this live virtual activity for a maximum of 1.0 AMA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the virtual live activity.

NURSING CREDIT INFORMATION

Purpose:

This program would be beneficial for nurses involved in the treatment of patients with COVID-19.

Credits: 1.0 ANCC Contact Hour

Credits:
1.0 ANCC Contact Hour

Accreditation Statement:

Ultimate Medical Academy/Conference Complete Management (CCM) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Awarded 1.0 contact hour(s) of continuing nursing education of RNs and APNs.

ACEP Category I Credit Statement

Approved by the American College of Emergency Physicians for 1.0 hour of ACEP Category I credit.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact: Med Learning Group at [email protected].

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at: http://www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Event Staff will be glad to assist you with any special needs (i.e. physical, dietary, etc.) Please contact Med Learning Group prior to the live event at [email protected]

Feel free to pass this invitation on to your physicians, fellows, physician assistants, nurses, pharmacists, healthcare practitioners, and any other colleagues that you believe would be interested in attending this free CME/CNE program.

 

REGISTER FOR LIVE VIRTUAL PROGRAM

 

Scroll to Top
Menu

Updates in the Treatment and Prevention of COVID-19​

Molnupiravir, an Oral Antiviral, Reduced the Risk of Hospitalization or Death in Patients with Mild-to-Moderate COVID-19

Molnupiravir, an investigational oral antiviral medicine, significantly reduced the risk of hospitalization or death by 50% in an interim analysis of the phase 3 MOVe-OUT trial. The planned analysis evaluated data from 775 at-risk, non-hospitalized adult patients with mild-to-moderate COVID-19. All patients enrolled had at least one risk factor associated with poor COVID-19 outcomes and were randomized within 5 days of symptom onset. At day 29, 7.3% of patients who received molnupiravir were either hospitalized or died, compared with 14.1% of placebo-treated patients (P= .0012). No deaths were reported in patients receiving molnupiravir, compared with 8 deaths in patients who received placebo. The incidence of any adverse event was comparable in the molnupiravir and placebo groups (35% and 40%, respectively). Discontinuation due to adverse events was lower with molnupiravir (1.3%) versus placebo (3.4%).

Reference:

https://www.contagionlive.com/view/molnupiravir-could-become-first-authorized-covid-19-pill